These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38697754)

  • 1. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent
    Zhao J; Pu D; Li Z; Zhang Y; Liu X; Zhuo X; Lu B; Cao B
    Virulence; 2024 Dec; 15(1):2348251. PubMed ID: 38697754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent
    Shi Q; Shen S; Tang C; Ding L; Guo Y; Yang Y; Wu S; Han R; Yin D; Hu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2361007. PubMed ID: 38801099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime-Avibactam Resistance Associated with Increased
    Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double
    Hu D; Wang S; Xu M; Zhang J; Luo X; Zhou W; Ma Q; Ma X
    Microbiol Spectr; 2024 Aug; 12(8):e0033124. PubMed ID: 38984824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
    Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
    mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
    Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Capitani V; Arcari G; Ambrosi C; Scribano D; Ceparano M; Polani R; De Francesco A; Raponi G; Ceccarelli G; Villari P; Palamara AT; Marzuillo C; Carattoli A
    mSphere; 2024 Sep; 9(9):e0042324. PubMed ID: 39171923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
    Antinori E; Unali I; Bertoncelli A; Mazzariol A
    Clin Microbiol Infect; 2020 Jul; 26(7):946.e1-946.e3. PubMed ID: 32061796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
    Shen Z; Ding B; Ye M; Wang P; Bi Y; Wu S; Xu X; Guo Q; Wang M
    J Antimicrob Chemother; 2017 Jul; 72(7):1930-1936. PubMed ID: 28333323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.